Dartmouth Contributors: 2009 ASCO Annual Meeting

  • Association between triglyceride (TG) levels, other clinical characteristics, and outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with erlotinib and bexarotene.
    Poster; Author: Dragnev; Co-Authors: Rigas, Dmitrovsky
  • ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate (IM) for primary and recurrent operable malignant GIST: Imaging findings and correlation with genotype and GLUT4 expression.
    Poster; Co-Author: Eisenberg
  • Correlation of gastrointestinal stromal tumor (GIST) gene expression signatures and response to imatinib mesylate in the Radiation Therapy Oncology Group phase II clinical trial S-0132.
    Discussed Poster; Co-Author: Eisenberg
  • Dose-ranging study of the combination of paclitaxel poliglumex and pemetrexed in advanced non-small cell lung cancer (NSCLC).
    Abstract; Author: Slagle; Co-Authors: Rigas, Dragnev
  • Influence of food on the pharmacokinetics (PK) of panobinostat (LBH589), an orally active histone deacetylase inhibitor, in patients with advanced cancer.
    Poster; Author: Lewis
  • Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: Efficacy and safety results.
    Discussed Poster; Co-Author: Ernstoff
  • Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581.
    Discussed Poster; Co-Author: Colacchio
  • A phase I study of intravenous (IV) milataxel in combination with carboplatin in adult patients with advanced malignant solid tumors.
    Abstract; Co-Author: Lewis
  • registHER: Treatment outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR+) metastatic breast cancer (MBC).
    Poster; Co-Author: Kaufman
  • Phase II trial of oral gimatecan in adults with recurrent glioblastoma.
    Discussed Poster; Co-Author: Fadul
  • Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial.
    Discussed Poster; Co-Author: Kaufman
  • Phase II study of recombinant IL-21 (rIL-21) plus sorafenib as second- or third-line therapy for metastatic renal cell cancer (mRCC): Final results.
    Discussed Poster; Co-Author: Ernstoff